MC
NEO icon

Moors & Cabot’s NeoGenomics NEO Stock Holding History

Moors & Cabot’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.5K Sell
13,000
-2,500
-16% -$26.3K ﹤0.01% 902
2025
Q4 		$182K Buy
15,500
+1,750
+13% +$18.9K 0.01% 859
2025
Q3 		$106K Buy
13,750
+1,750
+15% +$12.3K ﹤0.01% 880
2025
Q2 		$87.7K Buy
12,000
+2,000
+20% +$16.1K ﹤0.01% 859
2025
Q1 		$94.9K Buy
+10,000
New +$125K ﹤0.01% 840

Other funds holding NEO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Moors & Cabot's NEO Position: Q1 2026 in Review

Moors & Cabot reduced its NeoGenomics (NEO) stake by 16% in Q1 2026, selling an estimated $26.3K and leaving 13,000 shares worth $96.5K. The position accounts for ﹤0.01% of the portfolio, ranked #902.

Moors & Cabot first reported a position in NEO in Q1 2025 and has held it in 5 quarters since. The position peaked at $182K in Q4 2025. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.

  • Moors & Cabot held 13,000 shares of NeoGenomics worth $96.5K as of Q1 2026.
  • Moors & Cabot sold 2,500 NeoGenomics shares in Q1 2026, an estimated $26.3K.
  • NeoGenomics made up ﹤0.01% of Moors & Cabot's portfolio in Q1 2026, its #902 holding.
  • Moors & Cabot first reported a position in NeoGenomics in Q1 2025 and has held it in 5 quarters since.
  • Moors & Cabot's NeoGenomics position peaked at $182K in Q4 2025.
  • 253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.